Caris Life Sciences Unveils New Study Validating Optimal Sequencing for Breast Cancer Treatments

Reuters

08/13

Caris Life Sciences Unveils New Study Validating Optimal Sequencing for Breast Cancer Treatments

Caris Life Sciences Inc. has announced the publication of a new clinical study in Breast Cancer Research, examining the effectiveness and optimal sequencing of two antibody-drug conjugates, trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan $(SG)$, in HER2-negative breast cancer patients. The study concludes that T-DXd is more effective for patients with hormone receptor $(HR)$-positive tumors, while SG shows better results as the initial treatment for those with HR-negative and HER2-null tumors. This research is based on data from over 4,000 patients and highlights the importance of personalized treatment strategies. The full study has been made available on the Caris Life Sciences website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA50325) on August 13, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2559922602"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559922602\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559922602?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-13 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559922602","market":"fut","top_or_hot":-1,"title":"Caris Life Sciences Unveils New Study Validating Optimal Sequencing for Breast Cancer Treatments","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Caris Life Sciences Unveils New Study Validating Optimal Sequencing for Breast Cancer Treatments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Caris Life Sciences Inc. has announced the publication of a new clinical study in Breast Cancer Research, examining the effectiveness and optimal sequencing of two antibody-drug conjugates, trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan <a href=\"https://laohu8.com/S/SG\">$(SG)$</a>, in HER2-negative breast cancer patients. The study concludes that T-DXd is more effective for patients with hormone receptor <a href=\"https://laohu8.com/S/HR\">$(HR)$</a>-positive tumors, while SG shows better results as the initial treatment for those with HR-negative and HER2-null tumors. This research is based on data from over 4,000 patients and highlights the importance of personalized treatment strategies. The full study has been made available on the Caris Life Sciences website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA50325) on August 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Caris Life Sciences Unveils New Study Validating Optimal Sequencing for Breast Cancer Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCaris Life Sciences Unveils New Study Validating Optimal Sequencing for Breast Cancer Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-13 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Caris Life Sciences Unveils New Study Validating Optimal Sequencing for Breast Cancer Treatments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Caris Life Sciences Inc. has announced the publication of a new clinical study in Breast Cancer Research, examining the effectiveness and optimal sequencing of two antibody-drug conjugates, trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan <a href=\"https://laohu8.com/S/SG\">$(SG)$</a>, in HER2-negative breast cancer patients. The study concludes that T-DXd is more effective for patients with hormone receptor <a href=\"https://laohu8.com/S/HR\">$(HR)$</a>-positive tumors, while SG shows better results as the initial treatment for those with HR-negative and HER2-null tumors. This research is based on data from over 4,000 patients and highlights the importance of personalized treatment strategies. The full study has been made available on the Caris Life Sciences website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA50325) on August 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4104","symbol_name":"贸易公司与经销商","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDLKdvxy:1","article_id":"2559922602","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559922602","pubTimestamp":1755088269,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Caris Life Sciences Inc. has announced the publication of a new clinical study in Breast Cancer Research, examining the effectiveness and optimal sequencing of two antibody-drug conjugates, trastuzumab deruxtecan  and sacituzumab govitecan , in HER2-negative breast cancer patients. The study concludes that T-DXd is more effective for patients with hormone receptor -positive tumors, while SG shows better results as the initial treatment for those with HR-negative and HER2-null tumors. This research is based on data from over 4,000 patients and highlights the importance of personalized treatment strategies. The full study has been made available on the Caris Life Sciences website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4104":"贸易公司与经销商","BK4139":"生物科技","CAI":"Caris Life Sciences, Inc."},"translate_title":"Caris Life Sciences推出新研究，验证乳腺癌治疗的最佳测序","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAI":0.9},"content_text":"Caris Life Sciences Unveils New Study Validating Optimal Sequencing for Breast Cancer Treatments\n    \n\n        Caris Life Sciences Inc. has announced the publication of a new clinical study in Breast Cancer Research, examining the effectiveness and optimal sequencing of two antibody-drug conjugates, trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan $(SG)$, in HER2-negative breast cancer patients. The study concludes that T-DXd is more effective for patients with hormone receptor $(HR)$-positive tumors, while SG shows better results as the initial treatment for those with HR-negative and HER2-null tumors. This research is based on data from over 4,000 patients and highlights the importance of personalized treatment strategies. The full study has been made available on the Caris Life Sciences website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA50325) on August 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}